Orano Med
Matthieu Rodrigues has a solid background in quality management, safety, and environmental engineering. Matthieu has worked in various companies where Matthieu has been responsible for ensuring compliance with ISO certifications, managing safety systems, and improving quality management processes. With a strong educational background in engineering and quality management, Rodrigues has consistently delivered results in their roles, contributing to the success of the companies Matthieu has worked for.
This person is not in the org chart
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.